News for AxoGen, Inc. (AXGN)

ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative ...

Axogen and ADMA Biologics foresee minimal impact from President Trump's tariffs, highlighting strong domestic operations and resilient supply chains. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Full Year 2024 Revenue: USD 187.3 million, a 17.8% increase compared to 2023.Fourth Quarter 2024 Revenue: USD 49.4 million, up 15.1% compared to the prior year

Feb 25, 2025 / 01:00PM GMTOperator Good morning everyone. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and director, and Nir Nao

Axogen, Inc. (NASDAQ:AXGN) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ETCompany ParticipantsMichael Dale - Chairman and Chief Executive...

Quarterly Revenue: $49.4 million, surpassing the estimated $48.57 million and marking a 15.1% increase from the same quarter last year.Quarterly EPS: $0.01, ex

ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. ( AXGN), a global leader in developing and marketing innovative surgical solutio

Transaction Overview On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) executed a significant reduction in its holdings of KORU Medica

**media[538156]**

On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) made a significant move by acquiring an additional 2,851,982 shares of Health Cataly

ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. ( AXGN), a global leader in developing and marketing innovative surgical solutio

Axogen stock soars to 52-week high, touches $18.99

AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Axogen stock soars to 52-week high, hits $17.24

Axogen expects strong revenue growth for Q4 and full-year 2024, driven by performance across product portfolio.

ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. ( AXGN), a global leader in developing and marketing innovative surgical solutio